By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ocular Therapeutix, Inc. 

15 Crosby Drive

Bedford  Massachusetts  01730  U.S.A.
Phone: 781-357-4000 or 877-628-8998 Fax: 781-357-4001



Company News
Ocular Therapeutix (OCUL) Reports Second Quarter 2017 Financial Results And Provides Corporate Update 8/9/2017 7:24:40 AM
Ocular Therapeutix (OCUL) Appoints Daniel Bollag, Ph.D., As Senior Vice President, Regulatory Affairs, Pharmacovigilance And Quality 8/4/2017 7:47:32 AM
Ocular Therapeutix (OCUL) to Slash Jobs After FDA Rejection 8/2/2017 6:11:27 AM
Ocular Therapeutix (OCUL) To Report Second Quarter 2017 Financial Results 8/1/2017 6:59:09 AM
FDA Spurns Ocular Therapeutix (OCUL)'s Eye Drug Again Despite Eleventh Hour Scramble 7/12/2017 7:08:15 AM
Ocular Therapeutix (OCUL) Rockets After Company Submits FDA Amendment For Dextenza NDA 7/11/2017 7:42:45 AM
Ocular Therapeutix (OCUL) Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4) 6/26/2017 8:43:08 AM
Ocular Therapeutix (OCUL) Names Bristol-Myers Squibb (BMY)-Novartis AG (NVS) Vet As New CEO 6/23/2017 7:19:04 AM
Ocular Therapeutix (OCUL) Announces Executive Transition Plans 6/23/2017 6:21:10 AM
Ocular Therapeutix (OCUL) Presented Phase III Data For DEXTENZA At Association for Research in Vision & Ophthalmology Annual Meeting 5/11/2017 8:29:10 AM